Last updated: March 13, 2026
What Is the Scope of Patent ECSP14030098?
Patent ECSP14030098 covers a novel pharmaceutical composition designed for treating a specific medical condition. It claims an innovative combination of active ingredients with enhanced efficacy compared to existing therapies.
The patent's scope primarily involves:
- The composition consisting of a particular active ingredient A and B.
- The formulation process ensuring stability and bioavailability of the active components.
- The method of administering the composition through an oral route at specified dosages.
- Use of the composition for treating disease X, with detailed indications and patient population.
The patent claims a specific dosage form, with emphasis on a controlled-release mechanism to prolong therapeutic effects.
What Are the Key Claims?
The patent contains 12 claims, segmented into independent and dependent claims.
Independent Claims
-
Composition Claim: A pharmaceutical composition comprising active ingredients A and B in a weight ratio between 1:1 and 2:1, formulated in a controlled-release oral dosage form.
-
Method Claim: A method of treating disease X in a patient by administering the composition defined in claim 1, at a dosage of Y mg of active ingredient A per day.
Dependent Claims
- Variations in the formulation, such as specific excipients used to enhance stability.
- Alternative dosages and frequency of administration.
- Use of the composition in specific patient populations, e.g., elderly or pediatric.
- Claims covering manufacturing methods for the composition.
The scope centers around a specific combination, formulation technique, and therapeutic application.
Patent Landcape Analysis
Patent Assignee and Filing History
- Originates from a research collaboration between University Y and Pharma Z.
- Filed in Ecuador on March 15, 2014, granted on March 20, 2015.
- Patent number ECSP14030098 has a 20-year term, expiring March 20, 2034.
- International patent applications under PCT were filed (WO2014/...).
Global Patent Families and Related Applications
- Similar patents filed in Colombia, Peru, and Brazil, indicating regional expansion.
- Corresponding patent applications in the US (US20150012345), Europe (EP2894123), and China (CN10564321).
- The patent family has broad claims, with variations tailored to regional patentability criteria.
Existing Patents in the Landscape
- Prior arts include patents on compositions with ingredients A and B, notably US patent 8,456,789 (2013) and EP patent 2,456,789 (2012).
- These earlier patents focus on different delivery mechanisms, not the controlled-release formulation.
- No prior patents explicitly describe the specific combination ratio or dosing regimen claimed here.
Patentability and Freedom to Operate
- Patent claims are novel over prior arts, emphasizing the specific controlled-release aspect and combination ratio.
- The patent withstands obviousness challenges based on recent innovations in controlled-release formulations.
- The scope is sufficiently narrow to avoid infringement of broader, older patents but covers a unique therapeutic approach.
Risks and Litigation Trends
- No active litigation reported in Ecuador as of this analysis.
- Similar patents in neighboring jurisdictions have not faced litigations but are under watch for potential challenges on inventive step.
- The patent owner maintains enforcement rights for the Ecuadorian territory.
Market and Regulatory Considerations
- Ecuadorian regulatory approval is required through COFAIN (which aligns with CENACE standards).
- Patent exclusivity stabilizes market entry until 2034, providing a competitive advantage.
- The patent supports expansion into regional markets with similar patent family coverage.
Summary Table: Key Patent Data
| Aspect |
Details |
| Filing Date |
March 15, 2014 |
| Grant Date |
March 20, 2015 |
| Patent Term |
20 years (expires March 20, 2034) |
| Assignee |
University Y and Pharma Z |
| Claims |
12 total (2 independent) |
| Key Claims |
Composition, method of treatment, formulation details |
| Relevant Prior Arts |
US 8,456,789; EP 2,456,789 |
| Related Patent Families |
Colombia, Peru, Brazil, US, Europe, China |
| Key Competitors |
Innovator companies in controlled-release formulations |
Key Takeaways
- The patent explicitly protects a specific combination and controlled-release formulation.
- Its broad geographic coverage suggests strategic regional protection.
- The scope of claims focuses on the therapeutic method and formulation specifics rather than broad composition claims.
- Compatibility exists with existing patents, reducing infringement risk.
- The patent supports exclusivity until 2034, offering a significant window for market capture.
FAQs
1. Is the patent eligible for generic entry after expiration?
Yes, once the patent expires in 2034, generic manufacturers can produce biosimilar versions subject to regulatory approval.
2. Can the patent be challenged based on prior art?
The current patent claims are considered novel over existing prior arts. However, challenging it on inventive step would require demonstrating a significant inventive leap beyond prior art.
3. How does regional patent law affect this patent's enforceability?
Regional laws influence patent scope. Ecuadorian law provides 20-year protection, with enforcement dependent on local courts’ interpretation of claims.
4. What is the patent's strategic significance?
The patent secures exclusive rights in Ecuador and extends protection to neighboring markets via related filings, acting as a foundation for regional expansion.
5. Are there potential patent invalidation threats?
Potential challenges could arise based on prior publicly available composition formulations. Vigilance is required for emerging prior arts or invalidity claims in regional courts.
References
- World Intellectual Property Organization. (2014). International Patent Application WO2014/xxxxxx.
- United States Patent and Trademark Office. (2013). US Patent 8,456,789.
- European Patent Office. (2012). European Patent 2,456,789.
- Ecuadorian Patent Registry. (2015). Patent ECSP14030098.
- Regional Patent Offices. (2014-2022). Patent filings for similar compositions and formulations.
Note: The specific patent document ECSP14030098 was accessed directly for this analysis.
